Business
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
Posters include data across biomarker, translation and clinical studies supportingdevelopment of bexotegrast (PLN-74809), a dual-selective inhibitor of
About this update from Pliant Therapeutics, Inc.
[{"type":"text","content":"Posters include data across biomarker, translation and clinical studies supportingdevelopment of bexotegrast (PLN-74809), a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF Two posters selected for featured oral presentations at ATS 2023 Mini Symposiums SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company will present three scientific posters at the upcoming 2023 American Thoracic Society (ATS) International Conference, taking place May 19-24, 2023, in Washington, DC. “We are very pleased to be presenting these data from across the bexotegrast clinical development program, including data from our Phase 2a trial in patients with IPF,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics. “These presentations provide further insight into bexotegrast’s mechanism of action and support the continued development of this novel drug candidate.”The following abstracts are posted on ATS 2023’s online itinerary planner. Thematic Poster Session A67: Biomarkers, Mediators, and Translational Models for ILDDate: Sunday, May 21, 2023Presentation Time: 11:30 a.m. – 1:15 p.m. ETLocation: Area J, Hall C (Lower Level), Walter E. Washington Convention Center Abstract: Combining Dual αVβ6/αVβ1 Integrin Inhibitor, PLN-74809, With Standard-of-Care Therapies Has a Synergistic Effect on Reducing Fibrogenic Gene Expression in Fibrotic Human Lung Slices Pliant was also selected for featured oral presentations as part of the ATS 2023 Mini Symposiums program. Mini Symposium B17: Emerging Data on Disease and Symptom Based Therapeutics for Patients with IPF Date: Monday, May 22, 2023Presentation Time: 9:12 a.m. – 9:24 a.m. ETLocation: Ballroom B (Level 3), Walter E. Washington Convention Center Abstract: PLN-74809 Shows Favorable Safety and Tolerability and Indicates Antifibrotic Activity in a Phase 2a Study for the Treatment of Idiopathic Pulmonary Fibrosis Mini Symposium D19: New Perspectives on Translational Studies for Lung FibrosisDate: Wednesday, May 24, 2023Presentation Time: 9:00 a.m. - 9:12 a.m. ETLocation: Room 146 A-C (Street Level), Walter E. Washington Convention Center Abstract: Dual αVβ6/αVβ1 Integrin Inhibitor ...